Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia

Autor:	Ryan J. Caddell, Brian C. Betts, Jun-Min Zhou, Janelle Perkins, Farhad Khimani, Taiga Nishihori, Asmita Mishra, Joseph Pidala, Elizabeth DiMaggio, Claudio Anasetti, Lia Perez, Hugo F. Fernandez, Rebecca Tombleson
Rok vydání:	2020
Předmět:	Oncology Melphalan Cancer Research medicine.medical_specialty Transplantation Conditioning medicine.medical_treatment Fludarabine/Melphalan 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Internal medicine Medicine Humans Transplantation Homologous Busulfan Busulfan/fludarabine Chemotherapy business.industry Hematopoietic Stem Cell Transplantation Myeloid leukemia Reduced intensity Hematology Fludarabine Leukemia Myeloid Acute 030220 oncology & carcinogenesis Myelodysplastic Syndromes business Vidarabine 030215 immunology medicine.drug
Zdroj:	Leukemialymphoma. 61(7)
ISSN:	1029-2403
Popis:	Optimal conditioning chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains uncertain. Myeloablative regimens such as fludarabine/busulfan are favored over reduced-intensity fludarabine/melphalan (Flu/Mel); however, it is not known if Flu/Mel is inferior. We analyzed hematopoietic cell transplantation recipients with AML and MDS who received fludarabine with once-daily intravenous busulfan targeted to either area under the curve (AUC) 5300 µM*L/min (Flu/Bu 5300) (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc290b9dece0c6b1f98fd8e470ecb639 https://pubmed.ncbi.nlm.nih.gov/32476524 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.